CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference on Tuesday, November 29 at 2:00PM E.T.
A live webcast of the presentation will be available on the Investors page of the Company’s website at investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.
About TCR2 Therapeutics
TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors. The Company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR2, please visit www.tcr2.com.
Investor and Media Contact:
Senior Director, Investor Relations and Corporate Communications
- ROSEN, SKILLED INVESTOR COUNSEL, Encourages TuSimple Holdings, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm – TSP - November 26, 2022
- ROSEN, A RANKED AND LEADING FIRM, Encourages Enviva Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EVA - November 26, 2022
- ROSEN, A LEADING NATIONAL FIRM, Encourages International Game Technology PLC Investors to Secure Counsel Before Important December 13 Deadline in Securities Class Action – IGT - November 26, 2022